Skip to main content
63 search results for:

ASCO 2022 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. play
    29-06-2022 | ASCO 2022 | Conference coverage | Video

    Genitourinary cancer highlights from the 2022 ASCO Annual Meeting

    Tian Zhang shares her top picks from the genitourinary cancers tracks at the 2022 ASCO Annual Meeting, including the EVEREST trial and updates from TheraP and EV-301.

  2. play
    15-06-2022 | ASCO 2022 | Conference coverage | Video

    Breast cancer highlights from the 2022 ASCO Annual Meeting

    Harold Burstein takes us through the breast cancer studies that caught his attention at the 2022 ASCO Annual Meeting, including the DESTINY-Breast04 and LUMINA trials.

  3. 03-06-2022 | Channel

    2022 ASCO Annual Meeting

    Stay up to date with coverage from the 2022 ASCO Annual Meeting.

  4. 20-04-2023 | Urothelial cancer | At a glance | Article

    At a glance: Second and later line immunotherapy for advanced urothelial carcinoma

    Cohort 5 results presented at the 2022 ASCO Annual Meeting were also positive, with ORR and DCR of 10% and 61%, respectively, and a median DOR of 4.1 months.

  5. 09-02-2023 | Non-small-cell lung cancer | News | Article

    Real-world data show ‘modest’ survival gains with immunotherapy in older NSCLC patients

    This change meets the ASCO and ESMO threshold for a clinically meaningful benefit, suggesting that the adoption of ICIs has been associated with meaningful benefit for younger patients with NSCLC,” they summarize.

  6. 07-02-2022 | ASCO GU 2022 | Conference coverage | Channel

    2022 Genitourinary Cancers Symposium

    News articles and expert video interviews on the most practice-influencing GU cancer data from the 2022 Genitourinary Cancers Symposium.

  7. 04-06-2022 | ASCO 2022 | Conference coverage | Article

    Amivantamab updates confirm NSCLC efficacy for certain patients

    Fresh findings from the phase 1 CHRYSALIS and CHRYSALIS-2 trials have been presented at the 2022 ASCO Annual Meeting, adding support for the use of amivantamab in certain groups of patients with advanced non-small-cell lung cancer.

  8. 04-07-2022 | Breast cancer | News | Article
    guidelinesWatch

    ASCO updates multiple advanced breast cancer guidelines

    They continue: “However, other assays may have comparable clinical utility for treatment selection, but a lack of comparative data limits the ability to recommend them.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group J Clin Oncol 2022; doi:10.1200/JCO.22.00519 J Clin Oncol 2022; doi:10.1200/JCO.22.00520 J Clin Oncol 2022; doi:10.1200/JCO.22.01063

  9. play
    27-06-2022 | ASCO 2022 | Conference coverage | Video

    Highlights from ASCO 22 Annual Meeting: an expert discussion with Andrea Apolo & Elizabeth Plimack

    Andrea Apolo and Elizabeth Plimack discuss highlights of the ASCO 22 Annual Meeting. Here, they talk about some of the exciting new data presented on the use of antibody-drug conjugates targeting HER2, which are starting to show promise for the treatment of urothelial carcinoma (UC).  This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  10. 14-06-2022 | ASCO 2022 | Conference coverage | Article

    JAVELIN Bladder 100 exploratory analyses point to wide use of maintenance avelumab

    “These findings further support avelumab [first-line] maintenance as standard of care in this treatment setting,” conclude Bellmunt et al. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany 2022 ASCO Annual Meeting; Chicago, Illinois, USA: 3–7 June (Abstract 4559) 2022 ASCO Annual Meeting; Chicago, Illinois, USA: 3–7 June (Abstract 4560)

  11. 13-06-2022 | ASCO 2022 | Conference coverage | Article

    ctDNA identifies patients before late HR-positive breast cancer recurrence

    The CHiRP study was presented at the 2022 ASCO Annual Meeting in Chicago, Illinois, USA, by Marla Lipsyc-Sharf (Dana-Farber Cancer Institute, Boston, Massachusetts, USA) and simultaneously published in the Journal of Clinical Oncology .

  12. 06-06-2022 | ASCO 2022 | Conference coverage | Article

    DESTINY-Breast04 ‘practice changing’ for HER2-low metastatic breast cancer

    The results of the DESTINY-Breast04 trial are published simultaneously in The New England Journal of Medicine . medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group 2022 ASCO Annual Meeting; Chicago, Illinois, USA: 3–7 June N Engl J Med 2022; doi:10.1056/NEJMoa2203690

  13. 09-06-2022 | ASCO 2022 | Conference coverage | Article

    Biomarker may predict neoadjuvant treatment response in bladder cancer

    Thomas Flaig, from the University of Colorado Cancer Center in Aurora, USA, presented the findings at the 2022 ASCO Annual Meeting in Chicago, Illinois, USA.

  14. 09-06-2022 | ASCO 2022 | Conference coverage | Article

    Omitting radiotherapy may be feasible for luminal A, low-risk breast cancer

    medwireNews : Radiotherapy may not be necessary for patients with the luminal A breast cancer intrinsic subtype and a low clinical risk for recurrence, the LUMINA investigators reported at the 2022 ASCO Annual Meeting in Chicago, Illinois, USA.

  15. 08-06-2022 | ASCO 2022 | Conference coverage | Article

    Overall survival benefits shown for capivasertib in AI-resistant breast cancer

    The updated analysis of the phase 2 trial was presented by Robert Jones (Cardiff University, UK) at the 2022 ASCO Annual Meeting in Chicago, Illinois, USA.

  16. 08-06-2022 | ASCO 2022 | Conference coverage | Article

    Lung-MAP: Post-immunotherapy ramucirumab plus pembrolizumab improves NSCLC survival

    The study was simultaneously published in the Journal of Clinical Oncology . medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group 2022 ASCO Annual Meeting; Chicago, Illinois, USA: 3–7 June J Clin Oncol 2022; doi:10.1200/JCO.22.00912  

  17. 06-06-2022 | ASCO 2022 | Conference coverage | Article

    Acetaminophen may blunt ICI response in people with cancer

    They continue: “Altogether, our data suggest that Tregs are key players that may underlie the immunomodulatory effect of [acetaminophen], thus compromising [ICI] efficacy.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group 2022 ASCO Annual Meeting; Chicago, Illinois, USA: 3–7 June Ann Oncol 2022; doi:10.1016/j.annonc.2022.05.010

  18. 04-06-2022 | ASCO 2022 | Conference coverage | Article

    No benefit of maintenance cabozantinib in unselected patients with mUC

    ASCO 2022 video Robert Jones He also pointed out that the comparison was underpowered due to changes to the protocol as a result of the COVID-19 pandemic and the release of the JAVELIN Bladder 100 data supporting the use of avelumab in the maintenance setting.

  19. 05-06-2022 | ASCO 2022 | Conference coverage | Article

    TROPiCS-02 supports sacituzumab govitecan for HR+, HER2– advanced breast cancer

    The risk for progression or death was a significant 34% lower with the anti-Trop-2 antibody–drug conjugate than physician’s choice of single-agent chemotherapy in this heavily pretreated population, presenter Hope Rugo, from the University of California San Francisco in the USA, told the audience at the 2022 ASCO Annual Meeting in Chicago, Illinois, USA.

  20. 07-06-2022 | ASCO 2022 | Conference coverage | Article

    OS data reported from TheraP trial of LuPSMA in mCRPC

    The trial was not powered to assess OS, however, presenting author Michael Hofman (Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia) told the attendees of the 2022 ASCO Annual Meeting in Chicago, Illinois, USA.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.